PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24803295-11 2014 Preemptive administration of dexmedetomidine significantly attenuated the cytokine response after lipopolysaccharide (LPS) induced endotoxemia (TNF-alpha, IL-1beta, IL-6, P<0.01, respectively). Dexmedetomidine 29-44 interleukin 6 Mus musculus 165-169 26702389-6 2015 Our results provided evidence that Dex treatment attenuated LPS-activated NF-kappaB p65 activation, as well as the production of tumor necrosis factor-alpha, interleukin-6, and interleukin-1beta at the level of both mRNA and protein in spleen. Dexmedetomidine 35-38 interleukin 6 Mus musculus 158-171 35412062-11 2022 DEX treatment or miR-329-3p downregulation caused attenuated cognitive dysfunction and microglia activation as well as reduced IL-1beta, IL-6, and TNF-alpha levels in the hippocampus of the postoperative NCD mice. Dexmedetomidine 0-3 interleukin 6 Mus musculus 137-141 19181340-8 2009 The effects of dexmedetomidine on COX-2 expression and the production of PGE2, TNF-alpha, IL-1beta, IL-6, and IL-10 paralleled the effects of dexmedetomidine on iNOS. Dexmedetomidine 15-30 interleukin 6 Mus musculus 100-104 34278508-7 2021 The results showed that DEX treatment markedly increased the survival rate and neurological score, increased neuron survival, decreased the expression of the LC3, Beclin-1 and NF-kappaB proteins, as well as the cytokines IL-1beta, IL-6 and TNF-alpha, which indicated that DEX-mediated inhibition of autophagy and neuroinflammation ameliorated neuronal death following TBI. Dexmedetomidine 24-27 interleukin 6 Mus musculus 231-235 34278508-7 2021 The results showed that DEX treatment markedly increased the survival rate and neurological score, increased neuron survival, decreased the expression of the LC3, Beclin-1 and NF-kappaB proteins, as well as the cytokines IL-1beta, IL-6 and TNF-alpha, which indicated that DEX-mediated inhibition of autophagy and neuroinflammation ameliorated neuronal death following TBI. Dexmedetomidine 272-275 interleukin 6 Mus musculus 231-235 35538293-14 2022 And miR-665 knockdown attenuated the effect of DEX on inflammation damage (the levels of TNF-alpha, IL-1beta and IL-6 increased 1.36 times, 1.31 times, 1.43 time, respectively, and IL-10 decreased 1.68 times) and apoptosis from 17 to 25% (P < 0.01). Dexmedetomidine 47-50 interleukin 6 Mus musculus 113-117 33821300-5 2021 RESULTS: DEX significantly inhibited LPS-induced increases in the lung weight/body weight ratio and lung wet/dry weight ratio, decreased inflammatory cell infiltration, and decreased the production of proinflammatory factors, such as interleukin-1beta (IL-1beta), IL-6, and tumor necrosis factor alpha (TNF-alpha)in the lungs. Dexmedetomidine 9-12 interleukin 6 Mus musculus 264-268 34421084-7 2021 Dex inhibited the inflammatory response through decreasing the release and the mRNA expression of IL-1beta, IL-6, and TNF-alpha while increasing that of IL-10. Dexmedetomidine 0-3 interleukin 6 Mus musculus 108-112 32145512-9 2020 In vitro, dexmedetomidine pretreatment promoted BMDMs M2 activation, as evidenced by increased Arg1 and Mrc1 gene induction, decreased iNOS gene induction, inhibited phosphorated-signal transducer and activator of transcription 1 (p-STAT1) but enhanced p-STAT6 expression, much lower levels of proinflammatory TNF-alpha and IL-6, and higher levels of anti-inflammatory IL-10 cytokine secretion. Dexmedetomidine 10-25 interleukin 6 Mus musculus 324-328 33220278-9 2021 DEX inhibited LPS-induced TNFalpha, IL-6, and PGE2 productions and COX-2 mRNA expression, and the effects of DEX were reversed by yohimbine. Dexmedetomidine 0-3 interleukin 6 Mus musculus 36-40 32632241-8 2020 Mechanistically, DEX induced IL-6 secretion from aHSCs and promoted HCC progression via STAT3 activation. Dexmedetomidine 17-20 interleukin 6 Mus musculus 29-33 33220278-11 2021 Furthermore, T0070907 reversed the anti-inflammatory effects of DEX on TNFalpha and IL-6 productions in the cells. Dexmedetomidine 64-67 interleukin 6 Mus musculus 84-88 33179100-12 2021 Moreover, dexmedetomidine significantly decreased the levels of TNF-alpha, IL-1beta and IL-6 in the hippocampus. Dexmedetomidine 10-25 interleukin 6 Mus musculus 88-92 31572546-7 2019 Also Dex inhibited the elevation of serum interleukin-6 and tumor necrosis factor-alpha and increased lung HO-1 activity. Dexmedetomidine 5-8 interleukin 6 Mus musculus 42-87 31954762-9 2020 We further confirmed that DEX pretreatment reversed the EtOH-induced microglia activation in the DG as well as the upregulation of the hippocampal TNFalpha, MCP-1, IL-6, and IL-1beta mRNA levels. Dexmedetomidine 26-29 interleukin 6 Mus musculus 164-168 32065090-10 2020 Dexmedetomidine reduced the level of hippocampal IL-6, and it attenuated the increase in their levels caused by LPS. Dexmedetomidine 0-15 interleukin 6 Mus musculus 49-53 30964190-10 2019 Moreover, dexmedetomidine administration decreased contents of CD11b+CD45int, IL-6, and IL-1beta, but elevated TGF-beta content in treatment group. Dexmedetomidine 10-25 interleukin 6 Mus musculus 78-82 30071186-7 2018 RESULTS: We found that Dex exerted a potent anti-inflammatory effect by reducing the expression of M1 marker genes such as tumor necrosis factor alpha (P < 0.05), interleukin-1beta (IL-1beta) (P < 0.001) and IL-6 (P < 0.001). Dexmedetomidine 23-26 interleukin 6 Mus musculus 214-218 28555511-5 2017 We found that dexmedetomidine dose-dependently inhibited the production of tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 in the pouch and decreased the number of white blood cells (WBC) recruited into the pouch. Dexmedetomidine 14-29 interleukin 6 Mus musculus 113-131 29545877-8 2018 The content of tumor necrosis factor-alpha, interleukin-6 and albumin in bronchoalveolar fluid and MPO in lung tissue was significantly decreased in the 3-MA and DEX groups compared with the model group (P<0.05). Dexmedetomidine 162-165 interleukin 6 Mus musculus 44-57 29269298-9 2018 RESULTS: Dexmedetomidine at 20 mug/kg significantly attenuated pancreatic pathological injury, reduced serum levels of amylase, lipase, IL-1beta, IL-6, and tumor necrosis factor (TNF)-alpha, and decreased the expression of MPO in pancreatic tissue in both mouse models of pancreatitis. Dexmedetomidine 9-24 interleukin 6 Mus musculus 146-150 28784305-8 2017 After hepatic I/R injury, WT and NLRC5-/- mice pre-treated with DEX exhibited attenuated histological disruption, and reduced pro-inflammatory mediators, including tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6, IL-1beta and inducible nitric oxide synthase (iNOS), which was associated with the inactivated NF-kappaB pathway. Dexmedetomidine 64-67 interleukin 6 Mus musculus 205-223 28224201-11 2017 DEX suppressed the infiltration of macrophages and T cells into the kidneys following cisplatin treatment, which was involved in the inhibition of NF-kappaB activation and decreased expression of TNF-alpha, IL-1beta, IL-6, and MCP-1. Dexmedetomidine 0-3 interleukin 6 Mus musculus 217-221 28298895-12 2017 Further, Dex also inhibited mRNA expression of interleukin-6 and NADPH oxidase 4. Dexmedetomidine 9-12 interleukin 6 Mus musculus 47-60